Emerging therapeutic targets for patients with advanced prostate cancer.

Although recent advances in the treatment of castration-resistant prostate cancer (CRPC) have significantly improved patient outcomes, advanced prostate cancer is still associated with substantial morbidity and mortality, particularly in patients who develop resistance after multiple lines of therapy. Various cell signaling, DNA repair, and epigenetic enzymatic pathways are being targeted with small-molecule inhibitors in order to identify treatment strategies for patients with CRPC. In this review, we discuss novel targets and agents, studied preclinically and now being validated in clinical trials, including poly ADP-ribose polymerase (PARP), enhancer of zeste homologue 2 (EZH2), hedgehog pathway, MDM2/p53, and tyrosine kinase inhibitors. Further, we outline current approaches for novel prostate cancer vaccines such as DCVAC/PCa, PROSTVAC-V/F, MVI-816, CV9104, and PF-06753512. This wide spectrum of potential treatment strategies holds promise for additional improvements in the treatment of patients with CRPC, as these novel agents are aimed at targets known to be associated with growth and malignant progression of prostate cancer. If primary study endpoints are met, findings from ongoing phase III trials of well-tolerated and active combinations may provide new effective treatment options for advanced prostate cancer and thereby contribute to enhanced disease control in CRPC patients.

• Publication year

  2019

• Venue

  Cancer Treatment Reviews

• Publication date

  2019-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2019.03.002PMID 30913454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging Therapies in Metastatic Prostate Cancer

  2018cited by this paper
• Enhancer of zeste homolog 2 (EZH2) inhibitors

  2018cited by this paper
• Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

  2018cited by this paper
• PARP1-siRNA suppresses human prostate cancer cell growth and progression.

  2018cited by this paper
• Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells

  2018cited by this paper
• Perspectives on the clinical development of immunotherapy in prostate cancer

  2018cited by this paper
• Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer

  2018cited by this paper
• PD-1/PD-L1 pathway inhibitors in advanced prostate cancer

  2018cited by this paper
• Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

  2018cited by this paper
• Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

  2018cited by this paper
• Hedgehog in prostate cancer explained

  2018cited by this paper
• Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

  2018cited by this paper
• Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.

  2018cited by this paper
• Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator

  2018cited by this paper
• A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC).

  2018cited by this paper
• A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas

  2018cited by this paper
• Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.

  2018cited by this paper
• Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.

  2018cited by this paper
• Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer

  2018cited by this paper
• PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials.

  2018cited by this paper
• Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

  2017cited by this paper
• Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquin

  2017cited by this paper
• A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

  2017cited by this paper
• Reduction of immune inhibitory myeloid derived suppressor cells by low dose sunitinib combined with a cancer vaccine to provide therapeutic benefit to tumor-bearing mice.

  2017cited by this paper
• Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

  2017cited by this paper
• Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

  2017cited by this paper
• Reprogramming to resist

  2017cited by this paper
• Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

  2017cited by this paper
• First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results

  2017cited by this paper
• Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy

  2017cited by this paper
• Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.

  2017cited by this paper
• Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer

  2017cited by this paper
• 1183PSafety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of PF 06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC)

  2017cited by this paper
• 1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

  2017cited by this paper
• Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

  2017cited by this paper
• Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

  2017cited by this paper
• Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells

  2017cited by this paper
• PARP Inhibitors in Prostate Cancer

  2017cited by this paper
• Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer.

  2017cited by this paper
• Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

  2017cited by this paper
• Maintaining cell identity: PRC2-mediated regulation of transcription and cancer

  2016cited by this paper
• Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

  2016cited by this paper
• Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

  2016cited by this paper
• N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

  2016cited by this paper
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  2016cited by this paper
• Vaccine based immunotherapy regimen (VBIR) for the treatment of prostate cancer

  2016cited by this paper
• Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer

  2016cited by this paper
• Targeting EZH2 in cancer

  2016cited by this paper
• Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

  2015cited by this paper
• Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

  2015cited by this paper
• Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer

  2015cited by this paper
• Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Castration‐Resistant Prostate Cancer: AUA Guideline Amendment 2018

  2015cited by this paper
• Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

  2015cited by this paper
• Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).

  2015cited by this paper
• The Evolutionary History of Lethal Metastatic Prostate Cancer

  2015cited by this paper
• Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

  2014cited by this paper
• Masitinib (AB1010), from canine tumor model to human clinical development: where we are?

  2014cited by this paper
• mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

  2014cited by this paper
• CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor

  2014cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

  2013cited by this paper
• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• TAK‐441, a novel investigational smoothened antagonist, delays castration‐resistant progression in prostate cancer by disrupting paracrine hedgehog signaling

  2013cited by this paper
• Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.

  2013cited by this paper
• Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

  2012cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3

  2012cited by this paper
• Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  2012cited by this paper
• MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

  2010cited by this paper
• Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines

  2010cited by this paper
• Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

  2009cited by this paper
• Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

  2009cited by this paper
• Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

  2008cited by this paper
• Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells

  2007cited by this paper
• The p53 pathway: positive and negative feedback loops

  2005cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• The polycomb group protein EZH2 is involved in progression of prostate cancer

  2002cited by this paper

• Synergistic targeting strategies for prostate cancer

  2025cites this paper
• The landscape of genitourinary cancer vaccines: clinical advances and future opportunities.

  2025cites this paper
• Emerging Therapeutic Approaches in Prostate Cancer Management

  2025cites this paper
• Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer

  2024cites this paper
• Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy

  2024cites this paper
• Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook

  2024cites this paper
• Prostate cancer stem cells and their targeted therapies

  2024cites this paper
• Research progress on non-protein-targeted drugs for cancer therapy

  2023cites this paper
• Regulation of EZH2 Expression by INPP4B in Normal Prostate and Primary Prostate Cancer

  2023cites this paper
• Targeting sex steroid biosynthesis for breast and prostate cancer therapy

  2023cites this paper
• Advances in Immunotherapy and Vaccine for Prostate Cancer

  2023cites this paper
• Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants

  2023cites this paper
• Advances in cancer vaccines for immunotherapy of prostate cancer.

  2023cites this paper
• Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer

  2023cites this paper
• Identification of Lactate-Related Gene Signature for Prediction of Progression and Immunotherapeutic Response in Skin Cutaneous Melanoma

  2022cites this paper
• Pre-activation of autophagy impacts response to olaparib in prostate cancer cells

  2022cites this paper
• Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors

  2022cites this paper
• The 100 most-cited articles in castration-resistant prostate cancer: a bibliometric analysis

  2021cites this paper
• Lipoamino acid-modified GnRH analogs with receptor-mediated antiproliferative activity in prostate and ovarian cancer cells

  2021cites this paper
• Cell Plasticity and Prostate Cancer: The Role of Epithelial–Mesenchymal Transition in Tumor Progression, Invasion, Metastasis and Cancer Therapy Resistance

  2021influential citation
• Effect of prior cancer on survival outcomes for patients with advanced prostate cancer

  2021cites this paper
• Epigenetic reprogramming during prostate cancer progression: A perspective from development.

  2021cites this paper
• A Transcription Factor-Based Risk Model for Predicting the Prognosis of Prostate Cancer and Potential Therapeutic Drugs

  2021cites this paper
• An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate Genes

  2021cites this paper
• Is There a Role for Immunotherapy in Prostate Cancer?

  2020cites this paper
• Mitochondrial functional and structural impairment is involved in the antitumor activity of δ-tocotrienol in prostate cancer cells.

  2020cites this paper
• Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions

  2020cites this paper
• ABSTRACTS OF THE 30th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO)

  2020cites this paper
• Immunoconjugates for cancer targeting: a review of antibody-drug conjugates and antibody-functionalized nanoparticles.

  2020cites this paper
• Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer

  2020cites this paper
• Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7

  2020cites this paper
• Mechanisms of docetaxel resistance in prostate cancer: the key role played by miRNAs.

  2020cites this paper
• A four‐gene signature associated with clinical features can better predict prognosis in prostate cancer

  2020cites this paper
• Flavone-based arylamides as potential anticancers: Design, synthesis and in vitro cell-based/cell-free evaluations.

  2019cites this paper